We are live on ! Find out more
TRCT

Tower Research Capital (TRC) Portfolio holdings

AUM $3.85B
1-Year Est. Return 32.11%
This Fund
S&P 500
This Quarter Est. Return
+2.88%
1 Year Est. Return
+32.11%
3 Year Est. Return
+93.86%
5 Year Est. Return
+112.79%
10 Year Est. Return
+380.9%
AUM
$1.05B
AUM Growth
+$375M
Cap. Flow
+$361M
Cap. Flow %
34.49%
Top 10 Hldgs %
24.89%
Holding
5,677
New
1,360
Increased
1,920
Reduced
1,136
Closed
1,108

Sector Composition

Rank Sector Weight
1 Financials 6.05%
2 Technology 5.64%
3 Industrials 5.17%
4 Consumer Discretionary 4.28%
5 Healthcare 3.88%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
NTRA icon
3026
Natera
NTRA
$46.4B
$8K ﹤0.01%
638
-2,901
-82% -$32.3K
IMDX
3027
Insight Molecular Diagnostics
IMDX
$156M
$8K ﹤0.01%
106
+56
+112% +$5.23K
PAM icon
3028
Pampa Energía
PAM
$4.41B
$8K ﹤0.01%
+300
New +$6.93K
PDT
3029
John Hancock Premium Dividend Fund
PDT
$626M
$8K ﹤0.01%
+500
New +$7.9K
QMCO icon
3030
Quantum Corp
QMCO
$474M
$8K ﹤0.01%
126
+121
+2,420% +$8.78K
RDIB
3031
Reading International Class B
RDIB
$204M
$8K ﹤0.01%
657
+412
+168% +$5.3K
SMBK icon
3032
SmartFinancial
SMBK
$888M
$8K ﹤0.01%
530
-153
-22% -$2.5K
STAA icon
3033
STAAR Surgical
STAA
$1.21B
$8K ﹤0.01%
+1,442
New +$9.32K
TRS icon
3034
TriMas Corp
TRS
$1.44B
$8K ﹤0.01%
453
-198
-30% -$3.44K
UNB icon
3035
Union Bankshares
UNB
$109M
$8K ﹤0.01%
+213
New +$6.63K
VALU icon
3036
Value Line
VALU
$361M
$8K ﹤0.01%
518
-92
-15% -$1.5K
WLY icon
3037
John Wiley & Sons Class A
WLY
$2.66B
$8K ﹤0.01%
150
-506
-77% -$25.5K
WULF icon
3038
TeraWulf
WULF
$8.52B
$8K ﹤0.01%
718
+118
+20% +$1.31K
ATYR
3039
aTyr Pharma
ATYR
$50.1M
$8K ﹤0.01%
+208
New +$9.67K
VIVS
3040
VivoSim Labs
VIVS
$1.64M
$8K ﹤0.01%
+9
New +$6.04K
DLA
3041
DELISTED
Delta Apparel Inc.
DLA
$8K ﹤0.01%
366
+342
+1,425% +$7.08K
DSKE
3042
DELISTED
Daseke, Inc. Common Stock
DSKE
$8K ﹤0.01%
800
+200
+33% +$1.96K
SFE
3043
DELISTED
Safeguard Scientifics, Inc.
SFE
$8K ﹤0.01%
+674
New +$9.04K
PATI
3044
DELISTED
Patriot Transportation Holding, Inc. Common Stock
PATI
$8K ﹤0.01%
412
+263
+177% +$5.23K
CCF
3045
DELISTED
Chase Corporation
CCF
$8K ﹤0.01%
+133
New +$7.63K
UFAB
3046
DELISTED
Unique Fabricating, Inc.
UFAB
$8K ﹤0.01%
+650
New +$8.58K
RETA
3047
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$8K ﹤0.01%
+432
New +$8.4K
LOV
3048
DELISTED
Spark Networks SE American Depositary Shares
LOV
$8K ﹤0.01%
5,084
+4,442
+692% +$8.63K
CYAD
3049
DELISTED
Celyad Oncology SA American Depositary Shares
CYAD
$8K ﹤0.01%
318
CYRN
3050
DELISTED
CYREN Ltd.
CYRN
$8K ﹤0.01%
209
-633
-75% -$23.1K

Similar funds

Tower Research Capital (TRC)'s Q2 2016 Portfolio in Review

As of Q2 2016, Tower Research Capital (TRC) held 5,677 positions worth $1.05B, up 56% from $672M the previous quarter. Its ten largest holdings account for 25% of the portfolio.

Tower Research Capital (TRC) deployed $361M of net new capital in Q2 2016, opening 1,360 new positions and adding to 1,920 existing holdings. Its largest new stake was iShares Russell 1000 Growth ETF: 247,708 shares worth $6.21M.

By sector, the portfolio is most concentrated in Financials at 6.1% of assets, up from 2.5% a quarter earlier, followed by Technology and Industrials.

On the sell side, the largest reduction was iShares Russell 2000 ETF, an estimated $48M trimmed.

  • Tower Research Capital (TRC)'s largest Q2 2016 buy was iShares Russell 1000 Growth ETF: 247,708 shares worth $6.21M.
  • Tower Research Capital (TRC) added most to State Street SPDR Dow Jones Industrial Average ETF Trust in Q2 2016, an estimated $24.1M increase.
  • Tower Research Capital (TRC)'s biggest Q2 2016 reduction was iShares Russell 2000 ETF, cutting an estimated $48M.
  • Tower Research Capital (TRC) fully exited iShares Russell 2000 Growth ETF in Q2 2016, selling an estimated $9.09M.
  • Tower Research Capital (TRC)'s ten largest holdings make up 25% of its $1.05B portfolio in Q2 2016.
  • Tower Research Capital (TRC) opened 1,360 new positions and closed 1,108 in Q2 2016.
  • Tower Research Capital (TRC)'s portfolio value rose 56% quarter-over-quarter to $1.05B.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2016, filed 10 Aug 2016.